Please use this identifier to cite or link to this item: https://hdl.handle.net/1822/42262

TitleAntimicrobial peptides as novel anti-tuberculosis therapeutics
Author(s)Silva, João Pedro Martins Soares Castro
Appelberg, Rui
Gama, F. M.
KeywordsAntimicrobial peptides
Tuberculosis
Mycobacteria
Antibiotics
Peptide market
Pharmacoeconomical analysis
Issue date2016
PublisherElsevier
JournalBiotechnology Advances
CitationSilva, João Pedro; Appelberg, Rui; Gama, F. M., Antimicrobial peptides as novel anti-tuberculosis therapeutics. Biotechnology Advances, 34(5), 924-940, 2016
Abstract(s)Tuberculosis (TB), a disease caused by the human pathogen Mycobacterium tuberculosis, has recently joined HIV/AIDS as the world's deadliest infectious disease, affecting around 9.6 million people worldwide in 2014. Of those, about 1.2 million died from the disease. Resistance acquisition to existing antibiotics, with the subsequent emergence of Multi-Drug Resistant mycobacteria strains, together with an increasing economic burden, has urged the development of new anti-TB drugs. In this scope, antimicrobial peptides (AMPs), which are small, cationic and amphipathic peptides that make part of the innate immune system, now arise as promising candidates for TB treatment. In this review, we analyze the potential of AMPs for this application. We address the mechanisms of action, advantages and disadvantages over conventional antibiotics and how problems associated with its use may be overcome to boost their therapeutic potential. Additionally, we address the challenges of translational development from benchside to bedside, evaluate the current development pipeline and analyze the expected global impact from a socio-economic standpoint. The quest for more efficient and more compliant anti-TB drugs, associated with the great therapeutic potential of emerging AMPs and the rising peptide market, provide an optimal environment for the emergence of AMPs as promising therapies. Still, their pharmacological properties need to be enhanced and manufacturing-associated issues need to be addressed.
TypeArticle
Description"Available online 24 May 2016"
URIhttps://hdl.handle.net/1822/42262
DOI10.1016/j.biotechadv.2016.05.007
ISSN0734-9750
e-ISSN0734-9750
Publisher versionhttp://www.journals.elsevier.com/biotechnology-advances/
Peer-Reviewedyes
AccessOpen access
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_38987_1.pdf1,33 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID